Robotic Workstation Prints 2.4 Million Microarrays per Year
|
By LabMedica International staff writers Posted on 31 Dec 2009 |
|
Advance in the speed and efficiency of manufacturing microarrays allows highly precise printing of as many as 2.4 million microarrays per year with a single robotic workstation. The microarrays are tiny glass substrates that contain rows and columns of printed spots used for molecular diagnostics and scientific research.
The technological breakthrough was made by Arrayit Corporation (Sunnyvale, CA, USA); its current capacity is 640,000 microarrays per instrument annually. The enhanced automated microarray printing bandwidth increases company's competitiveness in the diagnostics marketplace.
Arrayit executive vice president and cofounder Todd Martinsky stated, "This technological advance represents an engineering tour de force that combines our expertise in laboratory automation, linear drive robotics, micromachining, surface chemistry and contact printing. Leveraging our core tech competencies and patented contact printing platform in this manner should further enhance our competitive differentiation in the diagnostics market."
Arrayit Corporation discovers, develops, and manufactures life science technologies and consumables for disease prevention, treatment, and cure. The company is currently developing early stage definitive diagnostic tests for ovarian cancer, Parkinson's disease, influenza A virus (H1N1) and other illnesses.
Related Links:
Arrayit Corporation
The technological breakthrough was made by Arrayit Corporation (Sunnyvale, CA, USA); its current capacity is 640,000 microarrays per instrument annually. The enhanced automated microarray printing bandwidth increases company's competitiveness in the diagnostics marketplace.
Arrayit executive vice president and cofounder Todd Martinsky stated, "This technological advance represents an engineering tour de force that combines our expertise in laboratory automation, linear drive robotics, micromachining, surface chemistry and contact printing. Leveraging our core tech competencies and patented contact printing platform in this manner should further enhance our competitive differentiation in the diagnostics market."
Arrayit Corporation discovers, develops, and manufactures life science technologies and consumables for disease prevention, treatment, and cure. The company is currently developing early stage definitive diagnostic tests for ovarian cancer, Parkinson's disease, influenza A virus (H1N1) and other illnesses.
Related Links:
Arrayit Corporation
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Electrolyte Analyzer
BKE-B
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Latest Molecular Diagnostics News
- Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging
- Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis
- GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026
- Clinical Trial Evaluates Liquid Biopsy for Early-Stage Breast Cancer Detection
- RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer
- Modeling Study Shows Blood-Based CRC Screening Could Prevent More Deaths Than Stool Tests
- Noninvasive Cervical Test Detects Endometrial Cancer for Triage
- AI Tool Classifies Pathogenic Variants in Severe Childhood Epilepsy
- Molecular Test Detects Barrett’s Esophagus to Guide Endoscopy Referral
- Blood-Based Metagenomic Test Detects Wide Range of Pathogens from Single Sample
- New RNA Detection Tool Shows Promise for HIV and Other Viral Testing
- Tissue-Specific Vesicle Isolation Expands Molecular Insights Into Liver Disease
- Whole Genome Sequencing Solution Targets Unsolved Rare Disease Cases
- Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer
- Study Shows How Genome Reference Bias Can Mislead Preventive Testing
- Genomic Screening Expands Detection of Treatable Conditions in Newborns
Channels
Clinical Chemistry
view channel
Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more
Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
Lung nodules are commonly detected during chest imaging and require careful risk assessment to determine whether follow-up imaging, additional testing, or biopsy is needed. With millions of patients evaluated... Read more
Hematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read more
Immunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read more
Pathology
view channel
AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read more
Technology
view channel
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Industry
view channel
Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
